Recurrent immune thrombocytopenic purpura with excellent prognosis

Authors

  • Garima Biyani Post Graduate Trainee, Institute of Child Health, Kolkata, West Bengal, India
  • Syed Md Azad Post Graduate Trainee, Institute of Child Health, Kolkata, West Bengal, India
  • Souvik Guha Post Graduate Trainee, Institute of Child Health, Kolkata, West Bengal, India
  • Rohit Kapoor Post Graduate Trainee, Institute of Child Health, Kolkata, West Bengal, India
  • Hriday De Post Graduate Trainee, Institute of Child Health, Kolkata, West Bengal, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20171290

Keywords:

Autoimmune disorder, Recurrent ITP

Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by increase in destruction of circulatory platelets and is the most common cause of acquired thrombocytopenia in childhood. ITP can be classified based on duration of thrombocytopenia as acute and chronic form. Recurrent ITP is defined as recurrence of symptoms, after at least three months of remission sustained without any treatment. It is a rare entity and seen in just 5% of all ITP cases. Further, its treatment is often cumbersome and warrants use of non-conventional drugs and splenectomy. Reported here is a case of ITP in a 10-year-old girl, who presented with three recurrences and all episodes were successfully treated with either oral Prednisolone or resolved spontaneously.

References

Guerrero AP, Musgrave JE, Lee EK. Immune globulin-responsive thrombocytopenia in acute post-streptococcal glomerulonephritis: report of a case in Hawai’i. Hawaii Med J. 2009;68:56-8.

Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4-13.

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-93.

Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14:515-9.

Choi SI, McClure PD. Idiopathic thrombocytopenic purpura in childhood. Can Med Assoc J. 1967;97:562-8.

Wilson DB. Acquired platelet defects. In: Orkin SH, Ginsburg D, Nathan DG, Look AT, Fisher DE, Lux S, eds. Nathan and Oski’s Hematology of Infancy and Childhood, 7th ed. Elsevier, Philadelphia; 2008;1533-90.

Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010;24:249-73.

Fujisawa K, Tani P, Piro L, McMillan R. The effect of therapy on platelet associated autoantibody in chronic immune thrombocytopenic purpura. Blood. 1993;81:2872-7.

Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by gluco corticosteroid administration. Blood. 1986;67:203-6.

Handin RI, Stossel TP. (1978) Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood. 1978;51:771-9.

Downloads

Published

2017-03-28

How to Cite

Biyani, G., Azad, S. M., Guha, S., Kapoor, R., & De, H. (2017). Recurrent immune thrombocytopenic purpura with excellent prognosis. International Journal of Research in Medical Sciences, 5(4), 1697–1699. https://doi.org/10.18203/2320-6012.ijrms20171290

Issue

Section

Case Reports